DR. LUCAS MORENO
Oncólogo Pediátrico

Dr. Lucas Moreno

El Dr. Lucas Moreno es oncólogo pediátrico y dedica su carrera a los ensayos clínicos en fase precoz en pediatría.  Inició su carrera en el hospital La Fe, Valencia, que continuó posteriormente en el Hospital Royal Marsden de Londres, mentorizado por Andy Pearson.

Desde 2013, dirige la Unidad de Ensayos Clínicos del Hospital Niño Jesús en Madrid centrada en Onco-Hematologia Pediátrica.

Su principal línea de investigación se centra en el neuroblastoma donde se ha consolidado como junior key opinión leader, desarrollando nuevos fármacos en el laboratorio y llevándolos a la clínica dentro de ensayos fase I/II dentro de los consorcios europeos ITCC (Innovative Therapies for Children with Cancer) y SIOPEN (European Neuroblastoma Research Network).

Es autor de 48 publicaciones en revistas internacionales e investigador principal en más de 20 ensayos clínicos en oncología pediátrica.

Current occupation

  • 03/2013 – Lead of the Clinical Research Unit for Paediatric Phase I/II Clinical Trials. Paediatric Haematology, Oncology & Stem Cell Transplant. Hospital Infantil Universitario del Niño Jesús, Madrid, Spain

  • 01/2015 – Consultant Paediatric Oncologist Hospital Infantil Universitario del Niño Jesús, Madrid, Spain

  • 01/2015 – Invited Clinical Investigator, CNIO, Spanish National Cancer Research Centre

  • 02/2015 – Honorary Clinical Research Fellow, School of Cancer Sciences, University of Birmingham, UK

Academic data

  • 1997-2003 Degree in Medicine and Surgery. Universidad de Granada, Spain

  • 2007-2008 Diploma de Estudios Avanzados. Department of Biochemistry and Molecular Biology. Universidad de Valencia, Spain (MD equivalent)

  • 2004-2008 Specialist training in Paediatrics (Especialista en Pediatría y sus Áreas Especificas). Ministerio de Sanidad. Hospital Universitario La Fe, Valencia, Spain

  • 2012 European PhD degree Cum Laude. Thesis title: Development of pharmacodynamic biomarkers of the PI3K pathway for childhood neuroblastoma, Directors: Prof. Andrew DJ Pearson (The Institute of Cancer Research, Sutton, UK) and Prof. Luis Madero (Hospital del Niño Jesus, Madrid, Spain). Department of Paediatrics. Universidad Autónoma de Madrid, Spain

  • 2015-2017 Master’s Degree in Hospital & Clinical Management. Universidad Nacional de Educación a Distancia

Experience in Paediatric Haematology/Oncology

  • 01/2016 – Juan Rodés Investigator, Instituto de Investigación Sanitaria La Princesa
  • 01/2013 – 01/2015 Río Hortega Post-Doctoral Investigator, Clinical Research Programme CNIO, Spanish National Cancer Research Centre
  • 07/2012 – 12/2012 Consultant Paediatrician Infanta Cristina University Hospital, Madrid, Spain
  • 06/2012 – 08/2015 Senior Investigator in Paediatric Oncology Drug Development & Honorary Consultant. The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research, Sutton, UK
  • 02/2012 – 06/2012 Clinical Research Fellow in Paediatric Oncology Drug Development The Institute of Cancer Research, Sutton, UK
  • 08/2011 – 01/2012 Oak Foundation Locum Consultant in Paediatric Oncology Drug Development The Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research, Sutton, UK
  • 09/2009 – 07/2011 Clinical Research Fellow in Paediatric Oncology Drug Development The Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research, Sutton, UK
  • 06/2008 – 08/2009 Clinical Fellow in Paediatric Oncology The Royal Marsden Hospital NHS Foundation Trust, Sutton, UK
  • 06/2004 – 05/2008 Residency training. Qualification as Specialist in Paediatrics (Especialista en Pediatria y sus Areas Específicas) awarded by Spanish Ministerio de Sanidad y Consumo.  Paediatric Oncology Unit, Hospital Infantil La Fe, Valencia, Spain

Ongoing funded projects – translational research

  • Desarrollo de nuevos fármacos y biomarcadores para alteraciones moleculares recurrentes de ALK,
    RAS/RAF/MAPK/MEK, TERT y CHK1 en neuroblastoma de alto riesgo. IP: Dr. Lucas Moreno (IIS La Princesa).
    AES2016, PI16/02114. 147.620 Euros. 2017-2019
  • Desarrollo experimental de nuevos fármacos dirigidos contra dianas moleculares para su uso en ensayos clínicos contra el neuroblastoma infantil (ALK y MEK): Fundación Inocente, 09/2015 a 08/2016, 30.000 EUR. IP Dr. Lucas Moreno
  • BEACON-Neuroblastoma phase II trial (PI L Moreno), Chief Investigator, Cancer Research UK
  • Functional imaging in the BEACON-Neuroblastoma trial (PI L Moreno), Imagine 4 Margo
  • Mechanisms of action of oncolytic virotherapy with Celyvir in childhood tumours, co-investigator (PI M Ramirez). Proyectos de Investigación en Salud 2013 – Instituto de Salud Carlos III
  • Use of predictive biomarkers to accelerate childhood cancer drug development. Co-investigator (PI ADJ Pearson). Christopher’s Smile Charity 3
  • Development of pharmacodynamic biomarkers of the PI3K pathway for children with neuroblastoma for the first-in-child phase I trial of a PI3K/mTOR inhibitor (L Moreno, L Chesler, M Garrett, ADJ Pearson), Biomedical Research Centre and Royal Marsden Paediatric Fund
  • Development of predictive biomarkers for patient selection of patients in upcoming phase I trials of ALK, MEK and MDM2 inhibitors for patient selection in early clinical trials in neuroblastoma (G Barone, D Gonzalez de Castro, L Moreno, ADJ Pearson) Christopher’s Smile Charity

Ongoing projects – academic clinical trials

  • A randomised phase IIb trial of bevacizumab added to temozolomide + irinotecan for children with
    refractory/relapsed neuroblastoma, EudraCT 2012-000072-42, International Chief Investigator. The University of Birmingham CRCTU

Publications

  1. Bautista FJ, Moreno L, Marshall L, Pearson ADJ, Geoerger B, Paoletti X. Revisiting the definition of dose-limiting
    toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children
    with Cancer Consortium. Eur J Cancer 2017 Epub ahead of print

  2. Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, SchulteJH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G,
    Pearson AD. Accelerating drug development for neuroblastoma – New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opin
    Drug Discov. 2017 Aug;12(8):801-811.

  3. Bautista FJ, Fioravantti V, de Rojas T, Carceller F, Lassaletta A, Moreno L. Medulloblastoma in children and adolescents: A systematic review of contemporary phase I and II clinical trials and biology update. Cancer Medicine 2017 (in press)

  4. Bautista F, Gallego S, Cañete A, Mora J, Díaz de Heredia C, Cruz O, Fernández JM, Rives S, Berlanga P, Hladun R, Juan Ribelles A, Madero L, Ramírez M, Fernández Delgado R, Pérez-Martínez A, Mata C, Llort A, Martín Broto J, Cela ME, Ramírez G, Sábado C, Acha T, Astigarraga I, Sastre A, Muñoz A, Guibelalde M, Moreno L; en nombre de la Sociedad Española de Oncología Pediátrica (SEHOP) y el Grupo de Nuevas Terapias en Oncología Pediátrica; Sociedad Española de Hematología y Oncología Pediátrica (SEHOP); New Drug Development Group in Pediatric Oncology. [Early clinical trials in paediatric oncology in Spain: a nationwide perspective]. An Pediatr (Barc). 2017 Mar 6. pii:S1695-4033(16)30232-6. doi: 10.1016/j.anpedi.2016.07.007

  5. Moreno L, Pearson ADJ, Paoletti X, Jimenez I, Geoerger B, Kearns PR, Zwaan CM, Doz F, Baruchel A, Vormoor J, Casanova M, Pfister SM, Morland B, Vassal G. Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective Nat Rev Clin Onc 2017 available online 16 may 2017

  6. Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, Elliott M, Moreno L, Barone G, Pearson AD, James PW, Tweddle DA, McNally RJ. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016 Oct 4. doi: 10.1038/bjc.2016.302 [Epub ahead of print]

  7. Bautista F, Van der Lugt J, Kearns PR, Mussai FJ, Zwaan CM, Moreno L. The development of targeted new agents to improve the outcome for children with leukemia. Expert Opin Drug Discov. 2016 Sep 27:1-12. [Epub ahead of print]

  8. Carceller F, Bautista FJ, Jiménez I, Hladun-Álvaro R, Giraud C, Bergamaschi L, Dandapani M, Aerts I, Doz F, Frappaz D, Casanova M, Morland B, Hargrave DR, Marshall LV, Vassal G, Pearson AD, Geoerger B, Moreno L. Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study. Eur J Cancer. 2016 Sep 20;67:130-140. doi: 10.1016/j.ejca.2016.08.008. [Epub ahead of print]

  9. Carceller F, Jerome NP, Miyazaki K, Collins DJ, Orton MR, d’Arcy JA, Wallace T, Moreno L, Pearson AD, Zacharoulis S, Leach MO, Marshall LV, Koh DM. Feasibility and applicability of diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging in routine assessments of children with high-grade gliomas. Pediatr Blood Cancer. 2016 Sep 12. doi: 10.1002/pbc.26216. [Epub ahead of print]

  10. Bautista F, Gallego S, Cañete A, Mora J, Diaz de Heredia C, Cruz O, Fernández JM, Rives S, Madero L, Castel V, Cela ME, Ramírez G, Sábado C, Acha T, Astigarraga I, Sastre A, Muñoz A, Guibelalde M, Moreno L. Landscape of early clinical trials for childhood and adolescence cancer in Spain. Clin Transl Oncol. 2016 Jul;18(7):708-13. doi: 10.1007/s12094-015-1421-9. Epub 2015 Oct 21.

  11. Carceller F, Fowkes LA, Khabra K, Moreno L, Saran F, Burford A, Mackay A, Jones DT, Hovestadt V, Marshall LV,
    Vaidya S, Mandeville H, Jerome N, Bridges LR, Laxton R, Al-Sarraj S, Pfister SM, Leach MO, Pearson AD, Jones C, Koh DM, Zacharoulis S. Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma. J Neurooncol. 2016 Aug;129(1):109-21. Doi: 10.1007/s11060-016-2151-8. Epub 2016 May 14.

  12. Moreno L, Rubie H, Varo A, Le Deley MC, Amoroso L, Chevance A, Garaventa A, Gambart M, Bautista F, ValteauCouanet D, Geoerger B, Vassal G, Paoletti X, Pearson AD. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials. Pediatr Blood Cancer. 2016
    Aug 24. doi: 10.1002/pbc.26192. [Epub ahead of print]

  13. Carceller F, Bautista FJ, Fowkes LA, Marshall LV, Sirvent SI, Chisholm JC, Pearson AD, Koh DM, Moreno L. Response Assessment in Paediatric Phase I Trials According to RECIST Guidelines: Survival Outcomes, Patterns of Progression and Relevance of Changes in Tumour Measurements. Pediatr Blood Cancer. 2016 Aug;63(8):1400-6. doi: 10.1002/pbc.26039. Epub 2016 May 3.

  14. De Rojas T, Bautista FJ, Madero L, Moreno L. The first step to integrating Adapted Common Terminology Criteria for Adverse Events (CTCAE) for Children, J Clin Oncol 2016 (in press)

  15. Moreno L, Garcia Ariza MA, Cruz O, Calvo C, Fuster JL, Salinas JA, Moscardó C, Portugal R, Merino JM, MaderoL, Citarabina liposomal para el tratamiento de la diseminación leptomeníngea en tumores del SNC en niños y adolescentes. An Pediatr (Barc) 2016 (in press)

  16. Jerome NP, Miyazaki K, Collins DJ, Orton MR, d’Arcy JA, Wallace T, Moreno L, Pearson AD, Marshall LV, Carceller F, Leach MO, Zacharoulis S, Koh DM. Repeatability of derived parameters from histograms following non-Gaussian diffusion modelling of diffusion-weighted imaging in a paediatric oncological cohort. Eur Radiol. 2016 Mar 22

  17. Moreno L & Smith J (Joint first), Heaton SP, Chesler L, Pearson ADJ, Garrett MD. Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma. Mol Oncol 2015 (in press)

  18. Schrey D, Carceller Lechón F, Malietzis G, Moreno L, Dufour C, Chi S, Lafay-Cousin L, von Hoff K, Athanasiou T, Marshall LV, Zacharoulis S. Multimodal therapy in children and adolescents with newly diagnosed atypical teratoid rhabdoid tumor: individual pooled data analysis and review of the literature. J Neurooncol. 2015 Nov 25. [Epub ahead of print]

  19. Moreno L, Pearson ADJ, Children’s clinical cancer trials: what needs to change to allow children access to new cancer drugs? Expert Rev Clin Pharmacol 2015 (in press)

  20. Hirsch S, Marshall LV, Carceller F, Pearson ADJ, Moreno L, Targeted approaches to childhood cancer: progress in drug discovery and development, Expert Opin Drug Discov 2015 2015 May;10(5):483-95.

  21. Schrey D, Vaidya S, Levine D, Pearson ADJ, Moreno L, Additional therapies to improve metastatic response to induction therapy in children with high risk neuroblastoma, J Pediatr Hematol Oncol 2015 Apr;37(3):e150-3.

  22. Miyazaki K, Jerome NP, Collins DJ, Orton MR, D’Arcy JA, Moreno L, Marshall LV, Carceller F, Pearson ADJ, Leach MO, Zacharoulis S, Koh DM, Demonstration of reproducibility of diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: A pilot study. Eur Radiol 2015 (in press)

  23. Moreno L, Marshall L, Pearson AD, Morland B, Elliott M, Campbell-Hewson Q,Makin G, Halford S, Acton G, Ross P, Kazmi-Stokes S, Lock V, Rodriguez-Lopez AM, Lyons JF, Boddy A, Griffin MJ, Yule M, Hargrave D. A phase I trial of AT9283 (a selective inhibitor of Aurora kinases) in children and adolescents with solid tumours:
    A Cancer Research UK study. Clin Cancer Res. 2014 Nov 4. pii: clincanres.1592.2014. [Epub ahead of print] PubMed PMID: 25370467.

  24. Vassal G, Rousseau R, Blanc P, Moreno L, Bode G, Schwoch S, Schrappe M, Skolnik J, Bergman L, BradleyGarelik MB, Saha V, Pearson A, Zwierzina H. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. Eur J Cancer. 2014 Nov 27. pii: S0959-8049(14)01065-X. doi: 10.1016/j.ejca.2014.10.029. [Epub ahead of print] PubMed PMID: 25434924

  25. Moreno L, Marshall LV, Pearson ADJ, At the frontier of progress for paediatric oncology: the neuroblastoma paradigm. Br Med Bull 2013; 108: 173-88

  26. Barone G, Tweddle DA, Shohet J, Chesler L, Moreno L, Pearson ADJ, van Maerken T. MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance. Curr Drug Targets 2014 Jan 5 Epub ahead of print

  27. Morgenstern D, Hargrave D, Marshall LV, Gatz SA, Barone G, Crowe T, Pritchard-Jones K, Zacharoulis S, Lancaster DL, Vaidya SJ, Chisholm JC, Pearson ADJP, Moreno L. Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs. The Royal Marsden experience. J Pediatr Hematol Oncol 2013 Dec 7, Epub ahead of print

  28. Moreno L, ALK targeted therapy for poor prognosis childhood cancers. Lancet Oncol 2013, May;14(6):439-40.

  29. Moreno L, Pearson ADJ. How can attrition rates be reduced in anticancer drug discovery? Expert Opin Drug Discov 2013, 8(4): 363-8

  30. Moreno L, Barone G, Park J, Pearson ADJ. About the benefits of immunotherapy for neuroblastoma. J Clin Oncol 2013; 31(5): 649-50

  31. Moreno L, Vaidya SJ, Pinkerton CR, Lewis IJ, Imeson J, Machin D, Pearson ADJ. Long term follow-up of children with high risk neuroblastoma: The ENSG5 trial experience. Pediatr Blood & Cancer 2013; 60(7): 1135-40

  32. Moreno L, Popov S, Jury A, Al Sarraj S, Jones C, Zacharoulis S. Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma. J Neurooncol 2012, 111(2):169-76

  33. Raghuram CP, Moreno L, Zacharoulis S. Is there a role for high dose chemotherapy with hematopoietic stem cell rescue in patients with relapsed supratentorial PNET? J Neurooncol 2012; 106(3):441-7

  34. Lashkari HP, Saso S, Moreno L, Athanasiou T, Zacharoulis S. Using different schedules of Temozolomide to treat low grade gliomas: a systematic review of their efficacy and toxicity. J Neurooncol 2011; 105(2):135-137

  35. Moreno L, Fernandez-Navarro JM, Del Mar Andres M, Bautista F, Tasso M, Verdeguer A. Institutional experience with clofarabine and cytarabine in relapsed paediatric acute myeloid leukaemia. J Pediatr Hematol Oncol 2012; 34(1):e17-21

  36. Moreno L, Chesler L, Hargrave D, Eccles SA, Pearson AJ. Preclinical Drug Development for Childhood Cancer. Expert Opin Drug Discov 2011;6(1):49-64

  37. Saenz P, Brugada M, de Jongh B, Sola, A, Torres E, Moreno L, Vento M. A Survey of Intravenous Sodium Bicarbonate in Neonatal Asphyxia among European Neonatologists: Gaps between Scientific Evidence and Clinical Practice. Neonatology 2011;99:170-176

  38. Bautista F, Moreno L, Fernandez-Navarro JM, Senent L, Andres MM, Castel V, Verdeguer A. Evaluation of chimerism by quantitative PCR analysis of DNA polymorphism after allogeneic hematopoietic stem cell transplantation in a pediatric population with malignancies. Pediatr Transplant 2011; 15(1):81-7

  39. Moreno L, Bautista F, Ashley S, Duncan C, Zacharoulis S. Does chemotherapy affect the visual outcome in children with optic pathway glioma?: A systematic review of the evidence. Eur J Cancer 2010;46(12):2253-9

  40. Moreno L, Pollack IF, Duffner PK, Geyer JR, Grill J, Massimino M, Finlay J, Zacharoulis S. Utility of Cerebrospinal Fluid (CSF) Cytology in Newly-Diagnosed Childhood Ependymoma. J Pediatr Hematol Oncol 2010;32(6):515-8

  41. Bautista F, Gómez-Chacón J, Costa E , Moreno L , Cañete A , Muro MD , Velázquez J , Castel V . Retained intravascular fragments following removal of indwelling central venous catheters: a single institution experience. J Pediatr Surg 2010;45(7):1491-5

  42. Andres MM, Costa E, Canete A, Moreno L, Castel V. Solid ovarian tumours in childhood: a 35-year review in a single institution. Clin Transl Oncol 2010; 12(4): 287-91

  43. Zacharoulis S, Ashley S, Moreno L, Gentet JC, Massimino M, Frapaz D. Treatment and Outcome Of Children With Relapsed Ependymoma: A Multi-institutional Retrospective Analysis. Childs Nerv Syst 2009; 26(7): 905-11

  44. Zacharoulis S, Moreno L. Ependymoma: an update. J Child Neurol 2009; 24(11):1431-8

  45. Moreno L, Bautista FJ, Zacharoulis S. Outcome of teenagers and young adults with ependymoma: The Royal Marsden experience. Childs Nerv Syst 2009; 25(9): 1047-52

  46. Moreno L, Garzon L, Bautista FJ, Fernandez JM, Andres MM, Verdeguer A. Diagnosis of paediatric anaplastic large cell lymphoma: A historical perspective from a single institution. Clin Transl Oncol 2009;11(5):318-21

  47. Bautista F, Moreno L, Andres MM, Fernandez-Navarro JM, Fernandez-Sanmartin M, Verdeguer A. Abdominal Pain as the First Manifestation of Primary Pancreatic Lymphoma. J Pediatr Hematol Oncol 2009; 31(3):222-223

  48. Moreno L, Andres MM, Verdeguer A, Alvarez O, Fernandez-Navarro JM, Fernandez-Sanmartin M. Can etoposide infusion during stem cell transplantation produce a febrile reaction mimicking bacterial sepsis? Bone Marrow Transplantation 2008;42(1):59-60

  49. Vila L, Moreno L, Fernandez-Navarro JM, Andres MM, Verdeguer A, Perez-Valle S, Sangüesa C, Berbel O, Castel V. Could other virus cause pediatric post-transplant lymphoproliferative disorder? Clin Transl Oncol 2008; 10(7):422-425

  50. Moreno L, Andres MM, Cañete A, Castel V. Synovial sarcoma in children. A single-centre experience. Clin Transl Oncol 2007; 9: 468-470

Membership of International Committees

  • SIOPEN (International Society of Paediatric Oncology European Neuroblastoma Research Network) Drug Development Group from September 2010
  • Member of SIOPEN Executive Committee from March 2017
  • Chair of the SIOPEN Drug Development Group from January 2015
  • ITCC (European consortium for Innovative Therapies with Children with Cancer) from October 2009
  • Member of the ITCC Clinical Trial Trials Committee (only Spanish representative) from February 2015

Other memberships

  • Member of the Executive Committee of RECLIP (Spanish Network for Paediatric Clinical Trials) from December 2016

  • Treasurer and member of the Executive Committee of the Spanish Society of Paediatric Haematology and Oncology (SEHOP) from June 2016

  • Flims Alumni Club from March 2009

  • Colegio de Médicos de Madrid (Colegiado 284620043)

  • Spanish Society of Paediatric Haematology and Oncology (SEHOP) from May 2009

  • General Medical Council (UK). Full Registration from April 2008 (GMC Reference Number 7008012). Specialist Registration in Paediatrics since August 2009

Published posters & key conference presentations

  • De Rojas, Bautista, Moreno et al. Diagnosis, management and outcome of children with Central Nervous System (CNS) primitive neuroectodermal tumors (PNET) in Spain: a study from the Spanish National Pediatric Oncology & Hematology Society (SEHOP). International Society for Paediatric Neuro-Oncology. Liverpool, June 2016.

  • Carceller, Bautista, Moreno et al. Participation of children and adolescents with central nervous system tumours in phase I trials within the ITCC European consortium. International Society for Paediatric NeuroOncology. Liverpool, June 2016.

  • Casanova & Moreno. Phase 1/2 study of nab-paclitxel in pediatric patients with recurrent/refractory solid tumors: a collaboration with innovative therapies for children with cancer (ITCC). SIOP, Dublin, 2016.

  • Moreno, Zhang and Bhatta. A Phase 1, Multicenter, Open-label, Dose De-escalation Study of the Oncolytic Virus, Talimogene Laherparepvec, in Pediatric Patients With Advanced Extracranial Solid Tumors. SIOP, Dublin, 2016.

  • Carceller, Bautista, Moreno et al. Prognostic factors of early mortality in children and adolescents participating in dose-finding trials within the ITCC european consortium. SIOP, Dublin, 2016.

  • Lucas Moreno, Andrew DJ Pearson, Dongjing Guo, Meredith S Irwin, Frank Berthold, Mike Hogarty, Takehiko Kamijo, Daniel Morgenstern, Claudia Pasqualini, Shifra Ash, Dominique Valteau-Couanet, Susan Cohn and Wendy B. London. Predicting “early” relapse/progression/death in children with INRGSS Stage M neuroblastoma using clinical and biologic factors: An INRG database analysis. Advances in Neuroblastoma Research, Cairns, Australia. June 2016.

  • Lucas Moreno, Michela Casanova, Julia C. Chisholm, Pablo Berlanga, Pascal B. Chastagner, Sylvain Baruchel, Carla Manzitti, Soledad Gallego Mélcon, Nicolas U. Gerber, Gianni Bisogno, Franca Fagioli, Birgit Geoerger, Julia Glade Bender, Isabelle Aerts, Christophe Bergeron, Pooja Hingorani, Ileana Elias, Mathew Simcock, Ruta Slepetis, Gilles Vassal. Phase 1/2 study of weekly nab-paclitaxel (nab-P) in pediatric patients (pts) with
    recurrent/refractory solid tumors (STs): dose-finding and pharmacokinetics (PK). J Clin Oncol 34, 2016 (suppl;abstr 10551)

  • Lucas Moreno, Jennifer Laidler, Veronica Moroz, Cormac Owens, Herve Rubie, Pablo Berlanga, Aurora Castellano, Karsten Nysom, Ruth L Ladenstein, Jochen Rossler, Christian M. Zwaan, Martin Elliott, Guy Makin, Dermot Murphy, Susan A Burchill, Neil Jerome, Raphael F. Rousseau, Pamela Kearns, Keith Wheatley, Andrew DJ Pearson, A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children
    with refractory/relapsed Neuroblastoma – BEACON-Neuroblastoma, a European Innovative Therapies for Children with Cancer (ITCC) – International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial, J Clin Oncol 33, 2015 (suppl; abstr TPS10082), ASCO 2015, Chicago

  • Fernando Carceller Lechon, Francisco Bautista, Irene Jimenez, Raquel Hladun-Alvaro, Cecile Giraud, Luca Bergamaschi, Madhumita Dandapani, Isabelle Aerts, Francois Doz, Didier Frappaz, Michela Casanova, Bruce Morland, Darren R Hargrave, Lynley V Marshall, Gilles Vassal, Andrew DJ Pearson, Birgit Geoerger, Lucas Moreno, Analysis of prognostic factors of clinical outcome in children and adolescents enrolled in phase I trials:
    a multicentre European collaborative study, J Clin Oncol 33, 2015 (suppl; abstr 10049), ASCO 2015, Chicago

  • Birgit Geoerger, Johannes Schulte, Christian M. Zwaan, Michela Casanova, Matthias Fischer, Lucas Moreno, Toby Trahair, Irene Jimenez, Hyoung Jin Kang, Alberto S. Pappo, Eric Schafer, Brian D. Weiss, Mary Ellen Healy, Ke Li, Tiffany Lin, Anthony Boral, Andrew DJ Pearson, Phase I study of ceritinib in pediatric patients (Pts) with malignancies harboring a genetic alteration in ALK (ALK+): Safety, pharmacokinetic (PK), and efficacy results, J
    Clin Oncol 33, 2015 (suppl: Abstract 10005), ASCO 2015, Chicago

  • A Pearson, M Casanova, L Moreno, J Schulte, D Ziegler, M Zwaan, F Doz, M Fischer, H J Kang, A Pappo, E Schafer, B Weiss, ME Healy, K Li, T Lin, A Boral, B Geoerger, Phase 1 Study of Ceritinib in Pediatric Patients with Malignancies Harboring a Genetic Alteration in ALK – Early Safety and Efficacy Results, European Paediatric Soft Tissue Sarcoma Group meeting, Lyon 2014

  • L Moreno, H Caron, B Geoerger, A Eggert, D Valteau-Couanet, P Brock, G Vassal, A Pearson. Accelerating Drug Development for Neuroblastoma: Summary of the New Drug Development Strategy Project Workshop from the Innovative Therapies for Children with Cancer (ITCC), European Network for Cancer Research in Children and Adolescents (ENCCA). Advances in Neuroblastoma Research 2014, Cologne.

  • D. Schrey, S. Vaidya, D. Levine, L. Moreno, A. Pearson, Inadequate response to induction chemotherapy in children with high-risk neuroblastoma: an institutional analysis. Pediatr Blood & Cancer 2013;60(S3):P-0244, SIOP 2013,

  • MW Kieran, D Hargrave, PY Wen, S Goldman, D Amakye, M Patton, F Tai, L Moreno. A phase3, multicenter, open-label, randomized, controlled study of the efficacy and safety of oral sonidegib (LDE225) versus temozolomide in patients with Hedgehog pathway-activated relapsed medulloblastoma. Society of NeuroOncology Symposium 2013.

  • D Hargrave, ADJ Pearson, L Moreno, B Morland, M Elliot, G Makin, Q Campbell-Hewson, P Wyld, S Halford, V Lock, J Lyons, A Boddy, M Yule. A Phase I Trial of AT9283 (a selective inhibitor of Aurora kinases) given for 72 hours every 21 days via intravenous infusion in children and adolescents with relapsed and refractory solid tumours. J Clin Oncol 30, 2012 (suppl; abstr 9542), ASCO 2012, Chicago

  • Moreno L, Heaton SR, Barker K, Chesler L, Garrett MG, Pearson ADJ. Isolation of neuroblastoma cells as a substrate for pharmacodynam ic biomarker assays to accompany early clinical trials in neuroblastoma. Eur J Cancer 2011; 47 (Suppl.1): S285. ECCO 2011, Stockholm

Invited Keynote Lectures

  • Invited speaker: SKC Neuroblastoma parent conference, London, November 2016

  • Invited speaker: Overview of treatment for relapsed disease. Neuroblastoma Update Course. Advances in Neuroblastoma Research, Cairns, Australia. June 2016

  • Invited speaker: Towards Biology-driven Drug Development for Childhood Cancers, 15th International Paediatric Haematology & Oncology Update Meeting, Edinburgh, UK. May 2016.

  • Ponente invitado: Inmunoterapia en Tumores Pediátricos. II Foro Translacional Inmunoterapia del Cáncer. GETICA – Grupo Español de Terapias Inmuno-biológicas en Cáncer, Sevilla, 2016.

  • Design of Biomarker-driven Targeted Drug Trials, Advances in Neuroblastoma Research, 2014, Cologne

  • Keynote lecture: Treatment of neuroblastoma in the new century. Neuroblastoma, cosa c’e di nuovo – Third Paediatric Haematology-Oncology Day of Bambino Gesu Paediatric Hospital, 2013, Rome

  • Keynote lecture: Ethical considerations in paediatric early clinical trials. Annual General Meeting of the Spanish Society of Pediatric Hematology and Oncology (SEHOP), Seville 2013

  • Three invited talks: Implementing new drugs and new therapeutic strategies for neuroblastoma into the clinic – Development of targeted agents in pediatric solid tumours – Update on clinical trials within ITCC, Update course of the Scandinavian Society for Paediatric Haematology and Oncology (NOPHO), Norway 2014.

  • How to incorporate new molecularly targeted therapies into treatment of paediatric acute myeloid leukaemia. La Fe Symposium on paediatric and adult Acute Myeloid Leukaemia, Valencia, 2013

Congresses

  • ANR, Advances in Neuroblastoma Research, invited speaker and oral presentation, Cairns, Australia June 2016  SIOPEN Spring Meeting, Speaker, Cairns, Australia, June 2016

  • ASCO, American Society of Clinical Oncology, Chicago, June 2016

  • Annual General Meeting of ITCC (Innovative Therapies for Children with Cancer consortium), Speaker, Paris, November 2015

  • SIOPEN Annual General Meeting, Speaker, Newcastle, UK, November 2015

  • ASCO, American Society of Clinical Oncology, Chicago, May 2015

  • SIOPEN Spring Meeting, Speaker, Dublin, April 2015

  • Annual General Meeting of ITCC (Innovative Therapies for Children with Cancer consortium), Speaker, Paris, November 2014

  • SIOPEN Annual General Meeting, Speaker, Vienna, Austria, October 2014

  • Congress of Spanish Society of Pediatric Hematology and Oncology (SEHOP), Las Palmas May 2014, Poster presentation

  • Advances in Neuroblastoma Research, invited speaker and poster presentation, Cologne, May 2014

  • SIOPEN Board Spring Meeting, Speaker, Catania, Spain, April 2014

  • Annual General Meeting of ITCC (Innovative Therapies for Children with Cancer consortium), Speaker, Paris, November 2013

  • Annual General Meeting of SIOPEN (European Neuroblastoma Research Network), Speaker, Paris, France, October 2012

  • SIOPEN Board Spring Meeting, Speaker, Valencia, Spain, April 2013

  • Annual General Meeting of ITCC (Innovative Therapies for Children with Cancer consortium), Speaker, Paris, October 2012

  • Annual General Meeting of SIOPEN (European Neuroblastoma Research Network), Speaker, Ghent, Belgium, September 2012

  • American Society of Clinical Oncology (ASCO), Chicago, US, June 2012 (poster presentation published in J Clin Oncol)

  • Annual General Meeting of SIOPEN, Speaker, London, UK, October 2011

  • European Cancer Congress, ECCO, Stockholm, Sweden September 2011 (oral communication published in Eur J Cancer)

  • SIOPEN Board Spring Meeting, Speaker, Oslo, Norway, April 2011

  • Annual General Meeting of SIOPEN, Speaker, Porto October 2010

  • Advances in Neuroblastoma Research, Stockholm, Sweden, June 2010, (1 oral communication, 1 selected poster)

  • Congress of Spanish Society of Pediatric Hematology and Oncology (SEHOP) May 2006 (Murcia, Spain), May 2007 (Sitges, Spain), May 2009 (Zaragoza, Spain), May 2010 (Almeria, Spain) and May 2011 (Valencia, Spain, Speaker on Drug Development session). Best communication award SEHOP, Zaragoza, Spain 2009

  • European Society for Blood and Marrow Transplantation (EBMT) 2007 (Lyon, France) and 2008 (Florence, Italy) (6 abstracts published in Bone Marrow Transpl)

  • Spanish Association of Pediatrics (AEPED), Valencia, Spain, June 2006 (6 abstracts published in An Esp Pediatr),

  • Spanish Society of Perinatology, Las Palmas, Spain 2005,

  • European Society of Pediatric Infectious Diseases (ESPID), Valencia, Spain 2004 (abstract published in Ped Inf Dis J).

  • Two published case presentations in EBMT training course, Genova, Italy 2007 (Bone Marrow Transpl 2008; 41(Suppl 2):S136, Bone Marrow Transpl 2008; 41(Suppl 2): S142).

Courses

  • Certificate of competency on Laboratory Animal Sciences for Researchers: Cateorgy C, Responsible for directing and designing laboratory animals procedures. CNIO – FELASA – Animalaria, March 2013

  • Certificate of competency on Laboratory Animal Sciences for Researchers: Category B, CNIO – Animalaria, March 2013

  • Good Clinical Practice – Spanish/European regulations. Universidad Autónoma de Madrid. February 2013

  • Workshop: ENCCA-ITCC-EU Tumour Groups, New Drug Development Strategy – NDDS, Neuroblastoma: pathways, targets and drug development, London, 10-11 December 2012 (speaker & coordinator)

  • Workshop: New oncology drug development for children and adolescents in Europe: Current status and where to go?, London, 5-6 December 2011

  • MHRA Paediatric Regulation Seminar, 10 February 2011

  • Good Clinical Practice Update. Royal Marsden Hospital NHS Trust, 7 December 2010

  • Paediatric Intermediate Life Support. Royal Marsden Hospital NHS Trust. 23 September 2010

  • Fundamentals of Clinical Research in the UK. NHS R&D Forum. December 2009

  • 2nd ITCC training days, early clinical trials and drug development. ITCC, Rome. October 2009

  • Methods in biomedical research. Universitat Oberta de Catalunya, Spain, 2009

  • Child Protection Awareness. Royal Marsden Hospital NHS Trust. April 2009

  • Good Clinical Practice. Royal Marsden Hospital NHS Trust. December 2008

  • 2nd ESO-SIOPE Masterclass in Pediatric Oncology. Ascona, Switzerland, November 2008

  • 10th ECCO-AACR-ASCO Workshop: Methods in Clinical Cancer Research. Flims, Switzerland June 2008, SIOPE Fellowship

  • European School of Haematology – European Blood and Marrow Transplantation Training Course (fellowship from organization): Blood and Marrow Transplantation in Children. Genoa, Italy, June 2007.

  • European School of Haematology Training Course (fellowship from organization): The 11th ESH-EBMT Training Course on Blood and Marrow Hematopoietic Stem Cell Transplantation. Alicante, April 2007

  • PhD courses: Intracelullar and intercelullar signaling, Molecular medicine technologies, Biochemical basis of fundamental and applied immunology, Regulatory mechanisms of human immune system, Biochemical basis of clinical toxicology. Universidad de Valencia. 2005-2006

  • Advanced Paediatric and Neonatal Cardiopulmonary Resuscitation. Valencia, December 2006

  • Methodology of Research. Valencia. November-December 2006

  • Emergencies and Treatment in Severely Ill Child. Madrid, November 2006

  • Advances in Umbilical Cord Blood Transplantation. Valencia. March 2006

Junior key opinion leader in paediatric oncology drug development and neuroblastoma. Highlights:

  • Responsible for the creation of the HNJ Clinical Research Unit for Paediatric Phase I/II Trials. Created in April 2013, this unit focuses in the design and development of first-in-child phase I trials and early clinical trials of molecularly targeted agents. In 4 years, between January 2013 and January 2017 the number of open clinical trials have increased from 9 to >40, including 12-first-in-child clinical studies of targeted agents.

  • Early clinical trials portfolio: Principal investigator for 9 first-in-child phase I trials and for other 11 clinical trials in our unit, participant in more than 40 early clinical trials for paediatric cancers.

  • Drug development for childhood cancers: Involved in the development of more than 10 phase I first-inchild trials. International Chief Investigator for the BEACON-Neuroblastoma trial, a randomised phase II trial run across 40 sites and 10 European countries which is the first randomised trial conducted in relapsed neuroblastoma in Europe.

  • Biomarker development, ongoing funded projects: 1) development of combination and biomarkers for high risk neuroblastoma, 2) Predictive biomarkers and stratified medicine: Development of NGS panel platform for paediatric cancers

  • Chair of the Drug Development Committee and new drugs/biology lead for the development of the new European frontline clinical trial for high risk neuroblastoma of the European Neuroblastoma Research Network (SIOPEN). From January 2015, member of the Clinical Trials Committee of the ITCC consortium.

  • Coordinator of the first Neuroblastoma New Drug Development Strategy initiative which identifies the targets and drugs which should be the focus for early clinical trials within the Innovative Therapies for Children with Cancer (ITCC) consortium

 

Reviewer for

  • The Lancet Oncology

  • European Journal of Cancer

  • British Journal of Cancer

  • Cancer

  • International Journal of Cancer

  • Clinical Pharmacology & Therapeutics

  • Pediatric Blood & Cancer

  • Oncogene

  • Oncotarget

  • Paediatrics

  • PLOS Medicine

  • PLOS One

  • Journal of Clinical Trials

  • Cochrane Childhood Cancer Review Group

  • Oncotargets and Medicine

  • Experimental & Molecular Medicine

  • Pediatric Drugs

  • World Journal of Pediatrics

  • Italian Neuroblastoma League

  • French Society for Paediatric Oncology (SFCE)

  • TRANSCAN-2 (European Comission, FP7)

  • Cancer Research UK

 

Member of the editorial board of Pediatric Blood & Cancer from 2017